Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

Phase 2 Completed 33 enrolled Neurotech Pharmaceuticals The Lowy Medical Research Institute Limited · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.

Timeline

Start: 2021-07-21
Primary completion: 2022-12-08
Completion: 2022-12-08

Outcome

Met primary endpoint

paper The eyes receiving sham treatment had 31% greater progression of neurodegeneration than the CNTF-treated eyes. PMID 30292541 ↗

paper The difference in mean area of photoreceptor loss was 0.05±0.03 mm2 (P = 0.04) at 24 months. PMID 30292541 ↗

Publications

Results Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Eliott D, Yan J, Bird A, Friedlander M; Macular Telangiectasia Type 2-Phase 2 CNTF Research Group. Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial. Ophthalmology. 2019 Apr;126(4):540-549. doi: 10.1016/j.ophtha.2018.09.041. Epub 2018 Oct 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ciliary neurotrophic factor	Cell therapy	—	Intravitreal